UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)
Ironwood PHARMACEUTICALS, INC.
(Name of Issuer)
-----------------------------------------------------------
Common Stock
(Title of Class of Securities)
-----------------------------------------------------------
4633X108
(CUSIP Number)
-----------------------------------------------------------
December 31, 2018
Date of Event Which Requires Filing of this Statement)
-----------------------------------------------------------
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
/x/ Rule 13d-1(b)
/ / Rule 13d-1(c)
/ / Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover
page shall not be deemed to be "filed" for the purpose of
Section 18 of the Securities Exchange Act of 1934 ("Act")
or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
Potential persons who are to respond to the collection of
information contained in this form are not required to
respond unless the form displays a currently valid OMB
control number.
1. Names of Reporting Persons and I.R.S. Identification No.
UBS Group AG (for the benefit and on behalf of the UBS
Asset Management division of UBS Group AG, see Item 7)
98-0186363
-----------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
a / /
b / / See Item 8 of attached schedule
-----------------------------------------------------------
3. SEC USE ONLY
-----------------------------------------------------------
4. Citizenship or Place of Organization
Switzerland
-----------------------------------------------------------
Number of 5. Sole Voting Power 7,632,375*
Shares Bene- 6. Shared Voting Power 0
ficially 7. Sole Dispositive Power 0
Owned by Each 8. Shared Dispositive Power 8,591,679*
Reporting
Person With:
-----------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person:
8,591,679*
-----------------------------------------------------------
10. Check if the Aggregate Amount in Row 9 Excludes Certain
Shares / /
-----------------------------------------------------------
11. Percent of Class Represented by Amount in Row 9
6.13%
-----------------------------------------------------------
12. Type of Reporting Person
HC
-----------------------------------------------------------
*The Reporting Person disclaims beneficial ownership of
such securities pursuant to Rule 13d-4 under the
Securities Exchange Act of 1934. In accordance
with SEC Release No. 34-39538 (January 12, 1998), this
filing reflects the securities beneficially owned
by the UBS Asset Management division of UBS Group AG
and its subsidiaries and affiliates on behalf of its
clients. This filing does not reflect securities, if any,
beneficially owned by any other division of UBS Group AG.
-----------------------------------------------------------
Cusip 46333X108
-----------------------------------------------------------
Item 1(a). Name of Issuer:
Ironwood PHARMACEUTICALS, INC.
Item 1(b). Address of Issuer's Principal Executive Offices:
301 Binney Street,
Cambridge, MA 02142
-----------------------------------------------------------
Item 2(a) Name of Persons Filing:
UBS Group AG
Item 2(b) Address of Principal Business Office or, if none,
Residence:
UBS Group AG's principal business office is:
Bahnhofstrasse 45
Zurich, Switzerland
Item 2(c) Citizenship:
Incorporated by reference to Item 4 of the cover pages.
Item 2(d) Title of Class of Securities:
Common Stock (the "Common Stock")
Item 2(e) CUSIP Number:
46333X108
-----------------------------------------------------------
Item 3. Type of Person Filing:
If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b) or (c), check whether the person filing is a:
/ / Broker or dealer registered under Section 15 of the Act;
/ / Bank as defined in Section 3(a)(6) of the Act;
/ / Insurance company as defined in Section 3(a)(19) of the Act;
/ / Investment company registered under Section 8 of the
Investment Company Act of 1940;
/ / An investment adviser in accordance with Rule 13d-1(b)(1)
(ii)(E);
/ / An employee benefit plan or endowment fund in accordance
with Rule 13d-1(b)(1)(ii)(F);
/X/ A parent holding company or control person in accordance
with Rule 13d-1(b)(1)(ii)(G);
/ / A savings association as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
/ / A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the
Investment Company Act of 1940;
/ / A non-U.S. institution in accordance with Rule 240.13d-1
(b)(1)(ii)(J);
/ / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. insititution in accordance with
Rule 240.13d-1(b)(1)(ii)(J), please specify the type of
institution.
-----------------------------------------------------------
Item 4 (a)-(c)(iv). Ownership:
Incorporated by reference to Items 5-11 of the cover pages.
The amount of shares beneficially owned includes shares of
common stock (CUSIP 528872302) issuable upon conversion of 5.25%
convertible notes due 2021 (CUSIP 528872AB0).
-----------------------------------------------------------
Cusip 46333X108
-----------------------------------------------------------
Item 5. Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that as
of the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following / /.
-----------------------------------------------------------
Item 6. Ownership of More than Five Percent on Behalf of
Another Person:
Accounts managed on a discretionary basis by the UBS Asset
Management division of UBS Group AG (UBS AM) have the right
to receive or the power to direct the receipt of dividends
from, or the proceeds from the sale of, the securities. To
the best of our knowledge, no account holds more than 5 percent
of the outstanding Securities being reported in this filing.
-----------------------------------------------------------
Item 7. Identification and Classification of the Subsidiary
Which Acquired the Security Being Reported on By the Parent
Holding Company:
Identification: UBS Asset Management (Americas) Inc.
Classification: IA
In addition to UBS Group AG, the following UBS AM affiliates
and subsidiaries are part of the UBS Asset Management division
included in this filing: UBS AG, UBS Asset Management
(Americas) Inc., UBS Asset Management Trust Company, UBS Asset
Management (Canada) Inc., UBS Asset Management (Australia) Ltd.,
UBS Asset Management (Hong Kong) Limited, UBS Asset Management
(Japan) Ltd., UBS Asset Management (Singapore) Ltd., UBS Asset
Management (Taiwan) Ltd., UBS Asset Management (Deutschland)
GmbH, UBS Asset Management (Italia) SGR SpA, UBS Asset
Management (UK) Ltd., UBS Asset Management Life Limited, and
UBS Hana Asset Management Co., Ltd., and UBS Asset Management
France SA.
UBS Group AG acquired UBS AG through the completion of a
share transfer offer on 28 November 2014 in which the
shareholders of UBS AG became shareholders of UBS Group AG
and their shares in UBS AG were transferred to UBS Group AG.
As a result, UBS Group AG controls UBS AG.
-----------------------------------------------------------
Item 8
UBS AM is composed of wholly-owned subsidiaries and branches
of UBS Group AG. UBS Group AG is reporting direct and
indirect beneficial ownership of holdings. None of the
reporting persons affirm the existence of a group within
the meaning of Rule 13d-5(b)(1).
-----------------------------------------------------------------------
-----------------------------------------------------------
Cusip 46333X108
-----------------------------------------------------------
Item 9 Notice of Dissolution of Group:
Not Applicable
-----------------------------------------------------------
Item 10 Certification:
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired
and are held in the ordinary course of business and were not
acquired and are not held for the purpose of or with the
effect of changing or influencing the control of the issuer
of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having
that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.
Date: February 13, 2019
UBS Group AG
By: /s/ Frank S. Pluchino
Frank S. Pluchino
pursuant to Power of Attorney, attached as Exhibit 1,
for the UBS Asset Management division
of UBS Group AG
By: /s/ Barry J. Mullen
Barry J. Mullen
pursuant to Power of Attorney, attached as Exhibit 1,
for the UBS Asset Management division
of UBS Group AG
EXHIBIT INDEX
Exhibit Number Exhibit Description
1 Power of Attorney
dated as of Feburary 12, 2018
EXHIBIT 1
Power of Attorney
Each of the following persons is hereby appointed as agent and
attorney-in-fact with power and authority to sign US Regulatory Filings,
including Schedule 13G and Form 13F, on behalf of UBS Group AG, UBS AG,
and their subsidiaries and affiliates in
the UBS Asset Management division of UBS Group AG:
Sal DiGangi
Barry Mullen
William Murphy
Frank Pluchino
All prior powers of attorney relating to the subject matter of this
Power of Attorney are hereby revoked. This Power of Attorney is
limited to the circumstances set forth herein.
This Power of Attorney shall expire
on 31 December 2020, but it may be revoked, in whole or in part, at any
time prior to that date. If a person identified above ceases
to perform regulatory filing services for UBS Asset Management
for any reason, this Power of Attorney shall be automatically
revoked with respect to that person. Nothing in this Power of Attorney
is intended to limit the authority of any other persons
to sign documents relating to the subject matter hereof to
the extent permitted by UBS Group Policy or otherwise.
APPROVED:
Date: As of 12 February, 2018
/s/ Markus Miederhoff
Markus Miederhoff
UBS Asset Management
General Counsel
Group Managing Director
/s/ William Ferri
William Ferri
UBS Asset Management
Head of Americas
Group Managing Director